因迪纳(Indena)是在华中药专利申请量和授权量最多的国外医药公司,但国内学界对其关注并不多见。本文首次较为全面地分析因迪纳在华专利现状及其专利战略,并结合我国中药行业存在的研发投入与专利创新能力不足、专利转化率较低等问题,从政府和企业两个层面提出解决问题的设想。

Indena is a foreign pharmaceutical company which possesses many traditional Chinese medicine patents in China., but domestic academia did not pay much attention to it .The paper analyzes the situation of patents and the patent strategy of Indena comprehensively for the first time, combined with analyzing the problems of traditional Chinese medicine industry in China, tries to put forward some suggestions from the level of the government and enterprise.

国家中医药管理局“中医药传统知识保护和传承人制度研究”( 编号：ZYYP-2010【003】)